LAURUSLABS2024-07-012024-09-30 LAURUSLABS2024-07-012024-09-30 LAURUSLABS2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member LAURUSLABS2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member LAURUSLABS2024-09-30 LAURUSLABS2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LAURUSLABS2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member LAURUSLABS2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LAURUSLABS2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member LAURUSLABS2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LAURUSLABS2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540222 LAURUSLABS NOTLISTED Laurus Labs Limited Equity 2024-04-01 2025-03-31 2024-10-24 2024-10-17 INR Crores Half yearly 14:00:00 14:50:00 2024-10-24 2024-10-24 true Cash Flow Indirect Not applicable Single segment Manufacturer of Generics API, Generics FDF, Ingredients and Synthesis 2024-07-01 2024-09-30 Unaudited Consolidated 12237000000.00 46000000.00 12283000000.00 5771700000.00 255900000.00 -544600000.00 1787200000.00 526100000.00 1075100000.00 3183500000.00 12054900000.00 228100000.00 0.00 228100000.00 231800000.00 -180900000.00 50900000.00 0.00 177200000.00 0.00 0.00 0.00 22300000.00 199500000.00 -4200000.00 195300000.00 198400000.00 1100000.00 194200000.00 1100000.00 1078300000.00 2 0.37 0.37 0.00 0.00 0.37 0.37 1. The above consolidated unaudited financial results of Laurus Labs Limited ( the Company ) including its subsidiaries (Collectively known as the Group ) and its associates (as mentioned in note 3) has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 24, 2024. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2024. 2. These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ( SEBI ). 3. Please see the pdf filed for Q2 FY25 Results to view the table. 4. a) During the quarter ended December 31, 2022, the Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited (LSCPL) in India on December 01, 2022. LSCPL has not commenced its operations. 5.The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'. 6. During the quarter ended June 30, 2024, the Company allotted 193,456 equity shares of Rs. 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. 7. The Board of Directors, at their meeting held on October 24, 2024 approved for the payment of interim dividend of Rs. 0.40/- per equity share of Rs. 2/- each. Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 24186100000.00 71100000.00 24257200000.00 11492200000.00 482600000.00 -1123300000.00 3527000000.00 1018000000.00 2135700000.00 6312300000.00 23844500000.00 412700000.00 0.00 412700000.00 415900000.00 -302500000.00 113400000.00 0.00 299300000.00 0.00 0.00 0.00 27000000.00 326300000.00 -1100000.00 325200000.00 323500000.00 2800000.00 322400000.00 2800000.00 1078300000.00 2 0.60 0.60 0.00 0.00 0.60 0.60 Other Expenses 3183500000.00 Other Expenses 6312300000.00 102200000.00 34012100000.00 5213400000.00 1714700000.00 2463000000.00 170000000.00 1266800000.00 0.00 491600000.00 1758400000.00 41000000.00 723100000.00 46095700000.00 21071300000.00 0.00 17499600000.00 432200000.00 17000000.00 8000000.00 69500000.00 18026300000.00 0.00 2099500000.00 41197100000.00 0.00 0.00 87292800000.00 1078300000.00 40261100000.00 41339400000.00 41441600000.00 6614200000.00 0.00 1011800000.00 7626000000.00 976800000.00 293200000.00 0.00 2360600000.00 11256600000.00 20603500000.00 10582300000.00 1643200000.00 32829000000.00 1118700000.00 271500000.00 375400000.00 0.00 34594600000.00 0.00 0.00 45851200000.00 87292800000.00 0.00 -2579700000.00 -1003900000.00 0.00 0.00 0.00 -301400000.00 0.00 0.00 68400000.00 0.00 0.00 0.00 2135700000.00 0.00 1048200000.00 0.00 0.00 0.00 -43800000.00 0.00 32400000.00 55600000.00 0.00 0.00 14100000.00 0.00 0.00 0.00 -639200000.00 -226500000.00 0.00 -991100000.00 0.00 390500000.00 199000000.00 573100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31800000.00 2620200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32400000.00 0.00 15100000.00 0.00 -2540900000.00 0.00 0.00 68200000.00 0.00 0.00 0.00 0.00 0.00 3708300000.00 1533400000.00 0.00 69600000.00 215600000.00 971300000.00 0.00 0.00 986600000.00 -981200000.00 24000000.00 -957200000.00 1389400000.00 432200000.00 (i) Remeasurement gains/(losses) on defined benefit plans 3800000.00 ii) Income tax relating to items that will not be reclassified to profit n or loss in subsequent periods -900000.00 (i) Remeasurement gains/(losses) on defined benefit plans 7600000.00 ii) Income tax relating to items that will not be reclassified to profit n or loss in subsequent periods -1900000.00 2900000.00 5700000.00 0.00 0.00 Exchange differences on translating the financial statements of foreign operations -7100000.00 Exchange differences on translating the financial statements of foreign operations -6800000.00 -7100000.00 -6800000.00 0.00 0.00